California Institute of Technology, 1200 Pharma and UC Oakland disclose PRMT5 inhibitors Oct. 15, 2020
Radioheads: Rayzebio closes $45M for targeted radiopharmaceuticals Oct. 14, 2020 By Cormac Sheridan Rayzebio Inc. raised $45 million in a series A round to build a platform company focused on developing targeted radiopharmaceuticals for solid tumor indications.Read More
Derazantinib active in intrahepatic cholangiocarcinoma with FGFR2 mutations/amplifications Oct. 14, 2020
RSS
